Flinton Capital Management LLC decreased its holdings in Intersect ENT, Inc. (NASDAQ:XENT) by 25.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 15,736 shares of the medical equipment provider’s stock after selling 5,264 shares during the period. Flinton Capital Management LLC owned about 0.05% of Intersect ENT worth $440,000 as of its most recent filing with the Securities & Exchange Commission.
Several other large investors have also bought and sold shares of XENT. FMR LLC grew its stake in shares of Intersect ENT by 247.7% in the second quarter. FMR LLC now owns 1,482,909 shares of the medical equipment provider’s stock worth $41,447,000 after acquiring an additional 1,056,389 shares in the last quarter. Alliancebernstein L.P. grew its stake in shares of Intersect ENT by 2,746.9% in the second quarter. Alliancebernstein L.P. now owns 931,505 shares of the medical equipment provider’s stock worth $26,036,000 after acquiring an additional 898,785 shares in the last quarter. Paulson & CO. Inc. acquired a new position in shares of Intersect ENT in the first quarter worth $10,978,000. EAM Investors LLC acquired a new position in shares of Intersect ENT in the second quarter worth $4,542,000. Finally, Citigroup Inc. grew its stake in shares of Intersect ENT by 9,294.3% in the second quarter. Citigroup Inc. now owns 101,271 shares of the medical equipment provider’s stock worth $2,831,000 after acquiring an additional 100,193 shares in the last quarter. Institutional investors and hedge funds own 83.12% of the company’s stock.
Shares of Intersect ENT, Inc. (XENT) opened at 28.70 on Wednesday. The stock’s 50 day moving average is $30.38 and its 200 day moving average is $26.01. Intersect ENT, Inc. has a 52-week low of $7.65 and a 52-week high of $33.25. The stock’s market capitalization is $837.72 million.
Intersect ENT (NASDAQ:XENT) last released its quarterly earnings results on Tuesday, August 1st. The medical equipment provider reported ($0.08) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.19) by $0.11. The business had revenue of $24.00 million during the quarter, compared to analyst estimates of $22.62 million. Intersect ENT had a negative net margin of 22.94% and a negative return on equity of 17.60%. The business’s revenue was up 24.4% on a year-over-year basis. During the same period last year, the business earned ($0.21) EPS. Equities research analysts expect that Intersect ENT, Inc. will post ($0.61) earnings per share for the current fiscal year.
WARNING: “Flinton Capital Management LLC Reduces Holdings in Intersect ENT, Inc. (XENT)” was first posted by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.com-unik.info/2017/10/11/flinton-capital-management-llc-reduces-holdings-in-intersect-ent-inc-xent.html.
XENT has been the subject of several research reports. BidaskClub downgraded shares of Intersect ENT from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, July 25th. Canaccord Genuity restated a “buy” rating and issued a $32.00 price target on shares of Intersect ENT in a research note on Wednesday, August 2nd. Deutsche Bank AG set a $31.00 price target on shares of Intersect ENT and gave the stock a “buy” rating in a research note on Wednesday, August 2nd. Zacks Investment Research raised shares of Intersect ENT from a “hold” rating to a “buy” rating and set a $33.00 price objective for the company in a research report on Thursday, October 5th. Finally, Bank of America Corporation lifted their price objective on shares of Intersect ENT from $33.00 to $40.00 and gave the stock a “buy” rating in a research report on Monday, September 11th. Four investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $27.70.
In related news, COO Richard E. Kaufman sold 12,500 shares of the firm’s stock in a transaction on Tuesday, July 25th. The shares were sold at an average price of $28.25, for a total transaction of $353,125.00. Following the completion of the sale, the chief operating officer now directly owns 169,821 shares of the company’s stock, valued at approximately $4,797,443.25. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Lisa D. Earnhardt sold 20,000 shares of the firm’s stock in a transaction on Monday, July 17th. The shares were sold at an average price of $29.03, for a total transaction of $580,600.00. Following the sale, the insider now directly owns 580,868 shares of the company’s stock, valued at $16,862,598.04. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 147,063 shares of company stock valued at $4,381,229. Company insiders own 13.70% of the company’s stock.
Intersect ENT Company Profile
Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.
What are top analysts saying about Intersect ENT Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Intersect ENT Inc. and related companies.